PMID: 7022994Jan 1, 1981Paper

Enzyme immunoassay for the prostate-specific acid phosphatase (E. C. 3.1.3.2)

Urological Research
H W BauerF Dati

Abstract

The clinical application of enzyme immunoassay for the determination of the prostate-specific acid phosphatase is reported. 227 sera were investigated in the diagnosis as well as in tumour monitoring and a good correlation with the clinical stage was found. In prostatic carcinomas 5 of 13 with stage T1, 11 or 12 patients with stage T2, 16 of 16 patients with T3 and 19 of 19 patients with stage T4 disease had values above 1 ng/ml. In prostatic adenomas (n = 69) in prostatitis (n = 40) and in other carcinomas of the urogenital tract (n = 28), renal carcinomas, carcinomas of the bladder and the penis) the values of the prostate-specific acid phosphatase measured by the enzyme immunoassay 131 of 137 were under 1 ng/ml. A comparison of random samples with the radioimmunoassay for this enzyme showed good correlation.

Citations

Jun 17, 2004·Journal of Basic and Clinical Physiology and Pharmacology·Fehmi Döner, Ibrahim Sari
Feb 8, 1989·Journal of Immunological Methods·M G PallaviciniR Barlett
Feb 27, 1986·Journal of Immunological Methods·A JohannssonC J Stanley
Oct 24, 1985·Journal of Immunological Methods·C J StanleyC H Self

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.